Insights

Gilead rescinds orphan status request for COVID-19 drug

Gilead has rescinded its request for orphan status for its potential COVID-19 antiviral remdesivir amid a furore over

Gilead rescinds orphan status request for COVID-19 drug

https://pharmaphorum.com/news/gilead-rescinds-orphan-status-request-for-covid-19-drug/

How to craft responsive clinical trials that are designed for success

Without the right design, right data and right decisions, idealised clinical trial plans cannot be translated into blueprints

How to craft responsive clinical trials that are designed for success

https://pharmaphorum.com/r-d/how-to-craft-responsive-clinical-trials-that-are-designed-for-success/

Lilly moves Crohn’s drug into phase 3, faces safety setback in Japan

Eli Lilly has had a mixed few days, posting promising trial results for mid-stage Crohn’s disease drug mirikizumab,

Lilly moves Crohn’s drug into phase 3, faces safety setback in Japan

https://pharmaphorum.com/news/lilly-moves-crohns-drug-mirikizumab/

Genentech signs deal with Parvus to tackle inflammatory diseases

Canada’s Parvus Therapeutics has signed a deal with Roche’s Genentech unit to develop, manufacture and market drugs for

Genentech signs deal with Parvus to tackle inflammatory diseases

https://pharmaphorum.com/news/genentech-signs-deal-with-parvus-to-tackle-inflammatory-diseases/

Understanding blockchain – a practical guide for life sciences companies

Within the life science industry, uptake of blockchain is in the early stages, but with investment levels in

Understanding blockchain – a practical guide for life sciences companies

https://pharmaphorum.com/digital/insights-digital/understanding-blockchain-life-sciences/

Exclusive insight from experts in the lyophilization industry

SMi Group reports: Leaders in the lyophilization industry to share their expertise and knowledge at SMi’s 4th annual

Exclusive insight from experts in the lyophilization industry

https://pharmaphorum.com/partner-content/exclusive-insight-from-experts-in-the-lyophilization-industry/

Pricing and Market Access Outlook 2018

This year’s edition of Pricing and Market Access Outlook, our first as IQVIA, identifies a trend towards models

Pricing and Market Access Outlook 2018

https://pharmaphorum.com/whitepapers/pricing-market-access-outlook-2018/

Pricing and market access – facts versus fiction

‘Pricing and Market Access Outlook: 2017 Edition’ includes fresh analysis from QuintilesIMS of market forces and pricing policy based on facts and figures behind approvals of new molecular entities in 2015.

Pricing and market access – facts versus fiction

https://pharmaphorum.com/whitepapers/pricing-market-access-facts-versus-fiction/

An integrated digital ecosystem to support patient outcomes, health-system sustainability, and return on investment

Demand for improved pharmaceutical care that enhances the patient experience is ever increasing, and meanwhile outcomes-based medicine

An integrated digital ecosystem to support patient outcomes, health-system sustainability, and return on investment

https://pharmaphorum.com/whitepapers/an-integrated-digital-ecosystem-to-support-patient-outcomes-health-system-sustainability-and-return-on-investment/

1 2

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Search

Advanced Search

Trending

Insights